Cyclophosphamide enhances anti-tumor effects of a fibroblast activation protein α-based DNA vaccine in tumor-bearing mice with murine breast carcinoma

Immunopharmacology and Immunotoxicology

Volumn 39, Issue 1, 2017, Pages 37-44

  Xia, Qiu ^a   Geng, Fei ^a   Zhang, Fang Fang ^a   Liu, Chen Lu ^a   Xu, Ping ^a   Lu, Zhen Zhen ^a   Xie, Yu ^a   Sun, Bo ^a   Wu, Hui ^a   Yu, Bin ^a   Kong, Wei ^a   Yu, Xiang Hui ^a   Zhang, Hai Hong ^a  

^a JILIN UNIVERSITY   (China)

Author keywords

cancer combination therapy; Cyclophosphamide; fibroblast activation protein ; immunomodulation; tumor immunology

Indexed keywords

CHEMOKINE RECEPTOR CXCR4; CYCLOPHOSPHAMIDE; CYTOKINE; DNA VACCINE; INTERLEUKIN 10; SEPRASE; TRANSCRIPTION FACTOR FOXP3; CANCER VACCINE; GELATINASE; MEMBRANE PROTEIN; SERINE PROTEINASE;

ADAPTIVE IMMUNITY; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER TISSUE; CD25+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; FEMALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN; SURVIVAL TIME; TUMOR GROWTH; ANIMAL; BAGG ALBINO MOUSE; CD4+ T LYMPHOCYTE; CELLULAR IMMUNITY; DRUG EFFECTS; IMMUNOLOGY; MAMMARY NEOPLASMS, EXPERIMENTAL; PATHOLOGY;

ANIMALS; CANCER VACCINES; CD4-POSITIVE T-LYMPHOCYTES; CD8-POSITIVE T-LYMPHOCYTES; CYCLOPHOSPHAMIDE; FEMALE; GELATINASES; IMMUNITY, CELLULAR; MAMMARY NEOPLASMS, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED BALB C; SERINE ENDOPEPTIDASES; VACCINES, DNA;

EID: 85006846902     PISSN: 08923973     EISSN: 15322513     Source Type: Journal    
DOI: 10.1080/08923973.2016.1269337     Document Type: Article

References (35)

1. Siegel R, Ma J, Zou Z, Jemal A., Cancer statistics, 2014. CA 2014;64:9–29.
2. LeBleu VS., Imaging the tumor microenvironment. Cancer J 2015;21:174–178.
3. Devaud C, John LB, Westwood JA, et al. Immune modulation of the tumor microenvironment for enhancing cancer immunotherapy. Oncoimmunology 2013;2:e25961.
4. Joyce JA, Fearon DT., T cell exclusion, immune privilege, and the tumor microenvironment. Science 2015;348:74–80.
5. Zitvogel L, Apetoh L, Ghiringhelli F, Kroemer G., Immunological aspects of cancer chemotherapy. Nature Rev Immunol 2008;8:59–73.
6. SteffenToni W, Arnulf W, Romuald S, et al. Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival. Nat Med 2012;18:1254–1261.
7. Ettinger DS, Karp JE, Abeloff MD, et al. Intermittent high-dose cyclophosphamide chemotherapy for small cell carcinoma of the lung. Cancer Treat Rep 1978;62:413–424.
8. Dussán KB, Magder L, Brodsky RA, et al. High dose cyclophosphamide performs better than monthly dose cyclophosphamide in quality of life measures. Lupus 2008;17:1079–1085.
9. Colleoni M, Rocca A, Sandri MT, et al. Low-dose oral methotrexate and cyclophosphamide in metastatic breast cancer:antitumor activity and correlation with vascular endothelial growth factor levels. Ann Oncol 2002;13:73–80.
10. Matar P, Rozados VR, Gervasoni SI, Scharovsky OG., Down regulation of T-cell-derived IL-10 production by low-dose cyclophosphamide treatment in tumor-bearing rats restores in vitro normal lymphoproliferative response. Int Immunopharmacol 2001;1:307–319.
11. Son CH, Bae JH, Lee HR, et al. Enhanced dendritic cell-based immunotherapy using low-dose cyclophosphamide and CD25-targeted antibody for transplanted Lewis lung carcinoma cells. J Immunother 2015;38:107–115.
12. Park JE, Lenter MC, Zimmermann RN, et al. Fibroblast activation protein, a dual specificity serine protease expressed in reactive human tumor stromal fibroblasts. J Biol Chem 1999;274:36505–36512.
13. Huber MA, Schubert RD, Peter RU, et al. Fibroblast activation protein:differential expression and serine protease activity in reactive stromal fibroblasts of melanocytic skin tumors. J Invest Dermatol 2003;120:182–188.
14. Micke P., Tumour-stroma interaction:cancer-associated fibroblasts as novel targets in anti-cancer therapy? Lung Cancer 2004;45:S163–S175.
15. Lee J, Fassnacht M, Nair S, et al. Tumor immunotherapy targeting fibroblast activation protein, a product expressed in tumor-associated fibroblasts. Cancer Res 2005;65:11156–11163.
16. Liu R, Li H, Liu L, et al. Fibroblast activation protein:a potential therapeutic target in cancer. Cancer Biol Ther 2012;13:123–129.
17. Cheng J, Valianou DM, Canutescu AA, et al. Abrogation of fibroblast activation protein enzymatic activity attenuates tumor growth. Mol Cancer Ther 2005;4:351–360.
18. Kalluri R, Zeisberg M., Fibroblasts in cancer. Nature Rev Cancer 2006;6:392–401.
19. Liao D, Luo Y, Markowitz D, et al. Cancer associated fibroblasts promote tumor growth and metastasis by modulating the tumor immune microenvironment in a 4T1 murine breast cancer model. PLoS One 2009;4:e7965.
20. Wen Y, Wang CT, Ma TT, et al. Immunotherapy targeting fibroblast activation protein inhibits tumor growth and increases survival in a murine colon cancer model. Cancer Sci 2010;101:2325–2332.
21. Chen M, Xiang R, Wen Y, et al. A whole-cell tumor vaccine modified to express fibroblast activation protein induces antitumor immunity against both tumor cells and cancer-associated fibroblasts. Scientific Rep 2015;5:14421.
22. Lo A, Wang LCS, Scholler J, et al. Tumor-promoting desmoplasia is disrupted by depleting FAP-expressing stromal cells. Cancer Res 2015;75:2800–2810.
23. Xia Q, Zhang FF, Geng F, et al. Anti-tumor effects of DNA vaccine targeting human fibroblast activation protein α by producing specific immune responses and altering tumor microenvironment in the 4T1 murine breast cancer model. Cancer Immunol Immunother 2016;65:613–624.
24. Loeffler M, Kruger JA, Niethammer AG, Reisfeld RA., Targeting tumor-associated fibroblasts improves cancer chemotherapy by increasing intratumoral drug uptake. J Clin Invest 2006;116:1955–1962.
25. Sierro SR, Donda A, Perret R, et al. Combination of lentivector immunization and low-dose chemotherapy or PD-1/PD-L1 blocking primes self-reactive T cells and induces anti-tumor immunity. Eur J Immunol 2011;41:2217–2228.
26. Zhang H, Wang Y, Liu C, et al. DNA and adenovirus tumor vaccine expressing truncated survivin generates specific immune responses and anti-tumor effects in a murine melanoma model. Cancer Immunol Immunother 2012;61:1857–1867.
27. Wang YQ, Zhang HH, Liu CL, et al. Enhancement of survivin-specific anti-tumor immunity by adenovirus prime protein-boost immunity strategy with DDA/MPL adjuvant in a murine melanoma model. Int Immunopharmacol 2013;17:9–17.
28. Couzin-Frankel J., Cancer immunotherapy. Science 2013;342:1432–1433.
29. Nguyen T, Urban J, Kalinski P., Therapeutic cancer vaccines and combination immunotherapies involving vaccination. ImmunoTargets Ther 2014;3:135–150.
30. Duraiswamy J, Kaluza KM, Freeman GJ, Coukos G., Dual blockade of PD-1 and CTLA-4 combined with tumor vaccine effectively restores T-cell rejection function in tumors. Cancer Res 2013;73:3591–3603.
31. Fassnacht M, Lee J, Milazzo C, et al. Induction of CD4+ and CD8+ T-cell responses to the human stromal antigen, fibroblast activation protein:implication for cancer immunotherapy. Clin Cancer Res 2005;11:5566–5571.
32. Chen X, Yang Y, Zhou Q, et al. Effective chemoimmunotherapy with anti-TGFβ antibody and cyclophosphamide in a mouse model of breast cancer. PLoS One. 2014;9:e85398.
33. Henry LR, Lee HO, Lee JS, et al. Clinical implications of fibroblast activation protein in patients with colon cancer. Clin Cancer Res 2007;13:1736–1741.
34. Scott A, Wiseman M, Welt G, et al. A phase I dose-escalation study of sibrotuzumab in patients with advanced or metastatic fibroblast activation protein-positive cancer. Clin Cancer Res 2003;9:1639–1647.
35. Zhang H, Liu C, Zhang F, et al. MUC1 and survivin combination tumor gene vaccine generates specific immune responses and anti-tumor effects in a murine melanoma model. Vaccine 2016;34:2648–2655.